Mabwell Reports Clinical Progress for COPD Candidate 9MW1911
At the European Respiratory Society International Congress 2026, Shanghai-based Mabwell unveiled promising Phase Ib/IIa data for its anti-ST2 monoclonal antibody, 9MW1911. The trial, involving 80 participants, demonstrated a significant reduction in chronic obstructive pulmonary disease exacerbations, particularly among patients receiving higher doses of the experimental therapy.
The randomized, double-blind study evaluated the safety and efficacy of 9MW1911 in former smokers with moderate-to-severe COPD. Patients received intravenous infusions ranging from 100 mg to 900 mg every four weeks. Researchers observed that the drug reached steady-state concentrations by week 12, with exposure levels increasing proportionally to the dose administered. Safety data indicated the treatment was generally well-tolerated.
Efficacy findings highlighted a notable dose-response relationship. The 900 mg cohort achieved a 100% reduction in the annualized rate of severe COPD exacerbations compared to the placebo group, while the 600 mg group showed a 47% reduction. For moderate-to-severe exacerbations, the treatment groups reported reductions of 81% and 24%, respectively. Following these results, Mabwell has finalized enrollment for a Phase IIb study and anticipates starting Phase III trials by the end of 2026. The drug has also received U.S. FDA clearance for a Phase IIa trial.
Comments (0)
No comments yet. Be the first!